8-K: Skye Bioscience Reports Positive Phase 2a Trial Progress and Full Year 2024 Financial Results

Skye Bioscience announces completion of enrollment in its Phase 2a CBeyondTM trial for nimacimab, a CB1 inhibitor targeting obesity, and reports financial results for 2024, projecting cash runway through Q1 2027.

Summary

• Skye Bioscience reported its fourth quarter and full year 2024 financial results and provided a business update on March 20, 2025.
• The company completed enrollment in its Phase 2a CBeyondTM trial of nimacimab for obesity and overweight, exceeding the initial target with 136 patients enrolled.
• Top-line data from the Phase 2a trial is expected in late Q3/early Q4 2025, ahead of schedule due to faster-than-expected enrollment.
• The Phase 2a dosing has been extended to 52 weeks to enhance long-term safety, tolerability, and efficacy data.
• Preclinical data released in November 2024 showed significant dose-dependent weight loss, fat mass loss with lean mass preservation, and improved glucose tolerance in a diet-induced obesity model in mice.
• Skye Bioscience expects its current capital to fund projected operations and key clinical milestones through at least Q1 2027.
• The company settled its insurance litigation case and received $2 million in cash proceeds in the fourth quarter of 2024.
• Research and development expenses for the year ended December 31, 2024, were $18.7 million, compared to $5.8 million for the same period in 2023.
• General and administrative expenses for the year ended December 31, 2024, were $17.7 million, compared to $7.9 million for the same period in 2023.
• Net loss for the year ended December 31, 2024, totaled $26.6 million, compared to $37.6 million for the year ended 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the accelerated trial timeline, promising preclinical data, and sufficient cash runway, although the company is still operating at a loss.

Positives

• Faster-than-expected enrollment in the Phase 2a trial allows for earlier reporting of top-line data.
• Extension of the Phase 2a trial to 52 weeks will provide more robust long-term data on safety and efficacy.
• Preclinical data supports the potential of nimacimab as a peripherally-restricted CB1 inhibitor.
• The company has a strong cash position, expected to fund operations through at least Q1 2027.
• Settlement of the insurance litigation case provides additional cash proceeds of $2 million.

Negatives

• The company reported a net loss of $26.6 million for the year ended December 31, 2024.
• Research and development expenses increased significantly to $18.7 million for the year ended December 31, 2024.
• General and administrative expenses also increased substantially to $17.7 million for the year ended December 31, 2024.

Risks

• The company's future success depends on the results of its clinical trials and the regulatory approval of its product candidates.
• The company may need to raise additional capital in the future to fund its operations.
• The biotechnology industry is highly competitive, and the company faces competition from other companies developing treatments for obesity and related conditions.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

Skye Bioscience anticipates reporting top-line data from its Phase 2a CBeyondTM trial in late Q3/early Q4 2025 and expects its current capital to fund operations through at least Q1 2027.

Management Comments

• Skyes prime accomplishment in 2024 was the initiation and rapid advancement of its comprehensive Phase 2a clinical study of nimacimab, a novel and differentiated CB1 inhibitor, said Punit Dhillon, President & CEO of Skye.
• We surpassed our enrollment target ahead of schedule and have to-date executed the Phase 2a clinical plan on target and within our budget.

Industry Context

The maturation of the obesity therapeutics landscape, including expanding clinical evidence, M&A, and licensing, highlights the strategic importance of alternative mechanisms of action with attributes differentiated from incretins, suggesting Skye's CB1 inhibitor approach could be valuable.

Comparison to Industry Standards

• The document mentions GLP-1 agonists like Wegovy, indicating that Skye is positioning nimacimab as a potential combination therapy or alternative to these established treatments.
• Companies like Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) are leaders in the obesity market, and Skye is aiming to differentiate itself with a peripherally-targeted CB1 inhibitor.
• The focus on peripheral CB1 inhibition is intended to avoid the central nervous system side effects associated with older CB1 inhibitors like rimonabant (Acomplia), which was withdrawn from the market due to psychiatric adverse events.

Management Changes

Legal Proceedings

• Skye settled its insurance litigation case and received $2 million in cash proceeds from its former D&O carrier in the fourth quarter of 2024.

Related Party Transactions

• Elimination of all related party balances, including the conversion of $5 million of debt to equity.

Stakeholder Impact

• Shareholders: The accelerated trial timeline and positive preclinical data could positively impact shareholder value.
• Employees: The company's progress and financial stability provide job security and potential for growth.
• Patients: Successful development of nimacimab could provide a new treatment option for obesity and related conditions.

Next Steps

• Presentation of nimacimab preclinical data at scientific/medical conferences in Q2 2025.
• Analyst event in conjunction with the Scientific Sessions of the American Diabetes Association (ADA) in June 2025.
• Reporting of Phase 2a CBeyond top-line data in late Q3/early Q4 2025.

Key Dates

Keywords

nimacimab, obesity, CB1 inhibitor, clinical trial, Phase 2a, financial results, Skye Bioscience, metabolic disorders, weight loss, GLP-1